Alivus Life Sciences FY26 Annual Earnings Summary

CDMO performance remained soft in Q2; management expects rebound in H2 but any delay in project ramp-ups or regulatory approvals could impact growth.

GPL segment declined due to customer inventory rationalization; management expects recovery in H2 but could not quantify, leaving uncertainty.

Management highlighted geopolitical risks as a key concern given the company's international presence, though diversification mitigates impact.

Analyst questioned why CDMO deal sizes are limited to $4-6M vs peers targeting $50-100M; management defended strategy citing high attrition and tax-driven manufacturing in Ireland.

Ongoing geopolitical conflicts and tariff uncertainties could disrupt supply chains and increase logistics and energy costs.

Solvent costs have increased significantly due to the war, though management expects to pass on costs to customers.

Capex spend has been slower than planned; while management says it won't impact near-term growth, delays in capacity expansion could limit medium-term scalability.

A flash fire led to a penalty from the Gujarat State Pollution Control Board; while management downplays it, repeated issues could affect operations.

Management acknowledged 4-4.5% annual price erosion across the portfolio, but expects to offset via next-gen processes and new launches.

Sholapur plant delayed by ~3 months to July 2026, and initial capacity reduced from 600kL to 450-500kL, though management says it won't impact growth.

A fire at the H plant impacted intermediate production, resulting in a 20 crore loss booked in other expenses, with minor spillover expected in Q1.

Management moderated timing for two CDMO deals to early H2 FY27, indicating possible delays from earlier expectations.